Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York. Show more
Location: 19 Vestry Street, New York, NY, 10013, United States | Website: https://brightmindsbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
607.3M
52 Wk Range
$23.18 - $93.40
Previous Close
$85.67
Open
$84.81
Volume
350,906
Day Range
$84.81 - $97.75
Enterprise Value
572M
Cash
51.39M
Avg Qtr Burn
-1.972M
Insider Ownership
20.40%
Institutional Own.
78.91%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
BMB-101 Details Epilepsy, Developmental and Epileptic Encephalopathy (DEE), Absence Seizures (AS) | Phase 2 Data readout | |
BMB-101 Details Prader-Willi Syndrome (PWS) | Phase 2a Update | |
BMB-105 Details Prader-Willi Syndrome (PWS) | Phase 1 Data readout |